• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Anitocabtagene autoleucel exhibits durable efficacy in high-risk advanced multiple myeloma

by | Jan 2, 2025 | Uncategorized

SAN DIEGO — Anitocabtagene autoleucel exhibited durable efficacy among heavily pretreated patients with high-risk relapsed or refractory multiple myeloma, results of the phase 2 iMMagine-1 study showed.Anitocabtagene autoleucel (Arcellx Inc. and Kite Pharma/Gilead...

Darzalex Regimen May Improve MRD Responses in Multiple Myeloma

by | Dec 21, 2024 | Uncategorized

Source: CureToday articles Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination. Read More

Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey

by | Dec 17, 2024 | Uncategorized

Source: CureToday articles Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®. Read More

Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma

by | Dec 10, 2024 | Uncategorized

Source: CureToday articles Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition. Read More

Tecvayli Effective Maintenance Therapy in Newly Diagnosed Multiple Myeloma

by | Dec 9, 2024 | Uncategorized

Source: CureToday articles Tecvayli alone or plus Revlimid has been found to be safe and may result in high MRD-negativity rates. Read More

Darzalex Faspro May Improve Progression, Survival in Smoldering Multiple Myeloma

by | Dec 9, 2024 | Uncategorized

Source: CureToday articles The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma. Read More
« Older Entries

Recent Content

  • Equecabtagene Autoleucel Shows Efficacy, Safety in Treatment of Patients With Heavily Pretreated Multiple Myeloma
  • Anitocabtagene autoleucel exhibits durable efficacy in high-risk advanced multiple myeloma
  • Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
  • Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
  • ASH 2024: Cilta-Cel Achieves Sustained MRD Negativity in Patients With Multiple Myeloma
  • Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies
  • Advancements in Multiple Myeloma Therapies and Operational Insights in Oncology Clinical Trials
  • Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT